Stocks / NASDAQ / Nexvet Biopharma plc

Nexvet Biopharma plc

Company Description

Nexvet Biopharma PLC operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel, specific biologics based on human biologics for companion animals. Its product candidates include NV-01, a monoclonal antibody (MAB) that targets and inhibits the function of nerve growth factor (NGF) for the control of pain associated with osteoarthritis in dogs; NV-02, a MAB that is an NGF inhibitor for the control of pain associated with degenerative joint disease, including osteoarthritis in cats; and NV-08, a fusion protein that is a tumor necrosis factor inhibitor for the treatment of chronic inflammatory diseases comprising atopic dermatitis in dogs. The company was founded in September 2014 and is headquartered in Dublin, Ireland. [Source: MarketWatch]

Company Website: